More Health Care Policy Decisions Ahead For France

15 September 1996

France's government is facing major decisions on health policy and health spending in the wake of a new report and recommendations from a high-level public health committee, the HCSP. The report remains unedited and is being distributed to those taking part in a national conference.

While life expectancy is increasing at a more sustained rate than in the past, the overall health picture of the nation has disturbing aspects. There is, for example, a very high death rate among men aged between 25 and 44, and a regrowth of certain types of cancer, especially lung cancer.

The committee notes that compared with other industrialized countries, France presents two particular features - that men's expectancy of life at birth is only 74, which puts them behind the Japanese, Swedes and Dutch, while life expectancy for women is 82, putting them in second place behind the Japanese.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight